129 related articles for article (PubMed ID: 25198571)
1. Serum anti-Müllerian hormone and polycystic ovary syndrome: a matter of methods?
Parco S; Novelli C; Princi T
Minerva Pediatr; 2014 Aug; 66(4):335-6. PubMed ID: 25198571
[No Abstract] [Full Text] [Related]
2. [Anti-Mullerian hormone in the major phenotypes of polycystic ovary syndrome].
Parahuleva N; Pehlivanov B; Orbecova M; Uchikova E; Ivancheva H
Akush Ginekol (Sofiia); 2014; 53(5):22-7. PubMed ID: 25558667
[TBL] [Abstract][Full Text] [Related]
3. [Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age].
Parahuleva N; Pehlivanov B; Orbecova M; Deneva T; Uchikova E
Akush Ginekol (Sofiia); 2013; 52 Suppl 1():16-23. PubMed ID: 24294740
[TBL] [Abstract][Full Text] [Related]
4. Serum anti-Mullerian hormone assessment of ovarian reserve and polycystic ovary syndrome status over the reproductive lifespan.
Tremellen K; Zander-Fox D
Aust N Z J Obstet Gynaecol; 2015 Aug; 55(4):384-9. PubMed ID: 26230428
[TBL] [Abstract][Full Text] [Related]
5. The relationship between serum anti-Müllerian hormone levels and the follicular arrest for women with polycystic ovary syndrome.
Li J; Li R; Yu H; Zhao S; Yu Y; Qiao J
Syst Biol Reprod Med; 2015 Apr; 61(2):103-9. PubMed ID: 25329139
[TBL] [Abstract][Full Text] [Related]
6. Anti-Müllerian hormone levels during hormonal contraception in women with polycystic ovary syndrome.
Somunkiran A; Yavuz T; Yucel O; Ozdemir I
Eur J Obstet Gynecol Reprod Biol; 2007 Oct; 134(2):196-201. PubMed ID: 17335955
[TBL] [Abstract][Full Text] [Related]
7. Serum AMH, FSH, and LH levels in PCOS.
Georgopoulos NA; Saltamavros AD; Decavalas G; Piouka A; Katsikis I; Panidis D
Fertil Steril; 2010 Feb; 93(3):e13; author reply e14. PubMed ID: 20060523
[No Abstract] [Full Text] [Related]
8. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome.
Pigny P; Jonard S; Robert Y; Dewailly D
J Clin Endocrinol Metab; 2006 Mar; 91(3):941-5. PubMed ID: 16368745
[TBL] [Abstract][Full Text] [Related]
9. Calprotectin is a potential prognostic marker for polycystic ovary syndrome.
Chen S; Jiang M; Ding T; Wang J; Long P
Ann Clin Biochem; 2017 Mar; 54(2):253-257. PubMed ID: 27217417
[TBL] [Abstract][Full Text] [Related]
10. What's in a number? The polycystic ovary revisited.
Raine-Fenning N
Hum Reprod; 2011 Nov; 26(11):3118-22. PubMed ID: 21926055
[No Abstract] [Full Text] [Related]
11. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism.
Dewailly D; Pigny P; Soudan B; Catteau-Jonard S; Decanter C; Poncelet E; Duhamel A
J Clin Endocrinol Metab; 2010 Sep; 95(9):4399-405. PubMed ID: 20610596
[TBL] [Abstract][Full Text] [Related]
12. Anti-Mullerian hormone is a better marker than inhibin B, follicle stimulating hormone, estradiol or antral follicle count in predicting the outcome of in vitro fertilization.
Kunt C; Ozaksit G; Keskin Kurt R; Cakir Gungor AN; Kanat-Pektas M; Kilic S; Dede A
Arch Gynecol Obstet; 2011 Jun; 283(6):1415-21. PubMed ID: 21562964
[TBL] [Abstract][Full Text] [Related]
13. Measurement of anti-Mullerian hormone: performances of a new ultrasensitive immunoassay.
Gruson D; Homsak E
Clin Biochem; 2015 Apr; 48(6):453-5. PubMed ID: 25575745
[TBL] [Abstract][Full Text] [Related]
14. Relationship between anti-Müllerian hormone (AMH) and insulin levels during different tanner stages in daughters of women with polycystic ovary syndrome.
Sir-Petermann T; Ladrón de Guevara A; Codner E; Preisler J; Crisosto N; Echiburú B; Maliqueo M; Sánchez F; Perez-Bravo F; Cassorla F
Reprod Sci; 2012 Apr; 19(4):383-90. PubMed ID: 22344736
[TBL] [Abstract][Full Text] [Related]
15. Ovarian reserve in women with polycystic ovary syndrome who underwent laparoscopic ovarian drilling.
Weerakiet S; Lertvikool S; Tingthanatikul Y; Wansumrith S; Leelaphiwat S; Jultanmas R
Gynecol Endocrinol; 2007; 23(8):455-60. PubMed ID: 17852413
[TBL] [Abstract][Full Text] [Related]
16. Anti-Müllerian hormone and polycystic ovary syndrome: assessment of the clinical pregnancy rates in in vitro fertilization patients.
Sahmay S; Guralp O; Aydogan B; Cepni I; Oral E; Irez T
Gynecol Endocrinol; 2013 May; 29(5):440-3. PubMed ID: 23461296
[TBL] [Abstract][Full Text] [Related]
17. Using cluster analysis to identify a homogeneous subpopulation of women with polycystic ovarian morphology in a population of non-hyperandrogenic women with regular menstrual cycles.
Dewailly D; Alebić MŠ; Duhamel A; Stojanović N
Hum Reprod; 2014 Nov; 29(11):2536-43. PubMed ID: 25267785
[TBL] [Abstract][Full Text] [Related]
18. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone.
Lauritsen MP; Bentzen JG; Pinborg A; Loft A; Forman JL; Thuesen LL; Cohen A; Hougaard DM; Nyboe Andersen A
Hum Reprod; 2014 Apr; 29(4):791-801. PubMed ID: 24435776
[TBL] [Abstract][Full Text] [Related]
19. Anti-Müllerian hormone - is it a clinically useful test?
Fenton A; Panay N
Climacteric; 2013 Feb; 16(1):1-2. PubMed ID: 23320765
[No Abstract] [Full Text] [Related]
20. The role of AMH in anovulation associated with PCOS: a hypothesis.
Homburg R; Crawford G
Hum Reprod; 2014 Jun; 29(6):1117-21. PubMed ID: 24770999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
